RE: Abstract Background SCIB1 and iSCIB1+, are novel DNA cancer vaccines incorporating CD8 and CD4 epitopes from TRP-2/gp100 into an antibody framework to allow direct and Fc targeting of activated dendritic cells. iSCIB1+ has additional epitopes8 Nov 2025 16:39
Cleaner - thanks for knocking quite a few years off my age. I’ll take that all day long.
The knowledgeable posters here, who can also explain the science in layman’s terms, can be counted on the fingers of one hand. That was the point I was making to Vas in my earlier post. The number of Recs they receive evidences this and illustrates how valuable and appreciated they are by investors here. They do not rely on AI and they do not try to curry favour.